Business
ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be
About this update from Immunitybio, Inc.
[{"type":"text","content":" CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022.\n\nDetails of the presentation can be found below.\n\n\n\nPiper Sandler Healthcare Conference\n\n\n\n\n\nDate:\n\n\n\n\nTuesday, November 29, 2022\n\n\n\n\n\nTime:\n\n\n\n\n2:30 - 2:55 pm EST\n\n\n\n\n\nFormat:\n\n\n\n\nFireside chat with Director and Senior Research Analyst Joseph Catanzaro, Ph.D.\n\n\n\n\n\nWebcast Link:\n\n\n\n\nhttps://event.webcasts.com/starthere.jsp?ei=1584249&tp_key=3f1d3e7b06\n\n\n\n\nA replay of the presentation will be available by visiting the \"Events” section of the ImmunityBio website and will be archived for 90 days.\n\nAbout ImmunityBio\n\nImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.\n\nImmunityBio’s clinical pipeline consists of 27 clinical trials—18 of which are in phase 2 or 3 development—across 13 indications in liquid and solid tumors (including bladder, pancreatic, and lung cancers) and infectious diseases (including SARS-CoV-2 and HIV). N-803 (Anktiva™), ImmunityBio’s lead cytokine fusion protein, is a novel IL-15 superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).\n\nThe company has established GMP manufacturing capacity at scale with cutting-edge cell therapy manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations, and development teams. For more information, please visit: www.immunitybio.com\n\nForward Looking Stateme...